Delta-Fly Pharma, Inc.

As of March 31, 2026, Delta-Fly Pharma, Inc. carries a market capitalization of 2.57B, placing it among publicly traded companies globally. Its enterprise value stands at 2.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Delta-Fly Pharma, Inc.'s next confirmed earnings release is scheduled for November 13, 2026.

As of March 31, 2026, Delta-Fly Pharma, Inc. has 13.17M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Delta-Fly Pharma, Inc. maintains a current ratio of 0.98, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 23, 2026, Delta-Fly Pharma, Inc.'s stock has declined approximately 84.94% over the past 52 weeks. The 50-day moving average sits at 106.28, while the 200-day moving average is 178.55.

These figures are as of March 31, 2026. Total book value stands at 33.98M, with working capital of -4.75M providing operational flexibility.